Tandem Diabetes Care, Inc. (TNDM) Stock Forecast
Data as of Sep 16, 2026Healthcare · Current price $17.98 (+10.44%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 23, 2026 | David Roman | Goldman Sachs | $28.00 | +55.7% |
| Feb 23, 2026 | Matt Miksic | Barclays | $56.00 | +211.5% |
| Feb 20, 2026 | Matt O'Brien | Piper Sandler | $21.00 | +16.8% |
| Jan 9, 2026 | David Roman | Goldman Sachs | $25.00 | +39.0% |
| Dec 17, 2025 | William Plovanic | Canaccord Genuity | $35.00 | +94.7% |
| Dec 17, 2025 | Anthony Petrone | Mizuho Securities | $21.00 | +16.8% |
| Oct 15, 2025 | Richard Newitter | Truist Financial | $16.00 | -11.0% |
| Sep 8, 2025 | Suraj Kalia | Oppenheimer | $22.00 | +22.4% |
| Aug 7, 2025 | William Plovanic | Canaccord Genuity | $24.00 | +33.5% |
| Aug 7, 2025 | Matt O'Brien | Piper Sandler | $14.00 | -22.1% |
| Jan 8, 2025 | Lee Hambright | Bernstein | $44.00 | +144.7% |
| Nov 7, 2024 | Jeff Johnson | Robert W. Baird | $37.00 | +105.8% |
| Nov 5, 2024 | Lee Hambright | Bernstein | $42.00 | +133.6% |
| Oct 4, 2024 | David Roman | Goldman Sachs | $46.00 | +155.8% |
| Oct 2, 2024 | Shagun Singh | RBC Capital | $65.00 | +261.5% |
| Aug 8, 2024 | William Plovanic | Canaccord Genuity | $57.00 | +217.0% |
| Aug 5, 2024 | Matt Miksic | Barclays | $58.00 | +222.6% |
| Aug 2, 2024 | Matt O'Brien | Piper Sandler | $55.00 | +205.9% |
| Aug 2, 2024 | Jeff Johnson | Robert W. Baird | $39.00 | +116.9% |
| Jun 10, 2024 | Steven Lichtman | Oppenheimer | $58.00 | +222.6% |
Top Analysts Covering TNDM
TNDM vs Sector & Market
| Metric | TNDM | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.50 | 2.25 | 2.42 |
| Analyst Count | 12 | 8 | 18 |
| Target Upside | +75.0% | +16187.2% | +19.5% |
| P/E Ratio | -6.19 | 3.79 | 38.67 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $1.07B | $1.08B | $1.11B | 16 |
| 2027-03-31 | $260M | $273M | $285M | 5 |
| 2027-06-30 | $282M | $296M | $309M | 6 |
| 2027-09-30 | $295M | $309M | $323M | 9 |
| 2027-12-31 | $328M | $344M | $359M | 5 |
| 2028-03-31 | $311M | $326M | $341M | 4 |
| 2028-06-30 | $324M | $340M | $355M | 6 |
| 2028-09-30 | $340M | $357M | $373M | 9 |
| 2028-12-31 | $376M | $395M | $412M | 4 |
| 2029-12-31 | $1.52B | $1.56B | $1.61B | 14 |
| 2030-12-31 | $1.72B | $1.77B | $1.83B | 8 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-1.30 | $-0.75 | $-0.49 | 14 |
| 2027-03-31 | $-0.19 | $-0.18 | $-0.17 | 4 |
| 2027-06-30 | $-0.07 | $-0.06 | $-0.06 | 5 |
| 2027-09-30 | $0.04 | $0.04 | $0.05 | 8 |
| 2027-12-31 | $0.25 | $0.26 | $0.28 | 4 |
| 2028-03-31 | $0.11 | $0.12 | $0.13 | 5 |
| 2028-06-30 | $0.20 | $0.22 | $0.23 | 7 |
| 2028-09-30 | $0.23 | $0.24 | $0.25 | 10 |
| 2028-12-31 | $0.40 | $0.43 | $0.45 | 5 |
| 2029-12-31 | $1.22 | $1.26 | $1.32 | 3 |
| 2030-12-31 | $1.67 | $1.73 | $1.80 | 3 |
Frequently Asked Questions
What is the analyst consensus for TNDM?
The consensus among 12 analysts covering Tandem Diabetes Care, Inc. (TNDM) is Buy with an average price target of $29.95.
What is the highest price target for TNDM?
The highest price target for TNDM is $160.00, set by Matthew Taylor at UBS on 2021-08-05.
What is the lowest price target for TNDM?
The lowest price target for TNDM is $14.00, set by Matt O'Brien at Piper Sandler on 2025-08-07.
How many analysts cover TNDM?
12 analysts have issued ratings for Tandem Diabetes Care, Inc. in the past 12 months.
Is TNDM a buy or sell right now?
Based on 12 analyst ratings, TNDM has a consensus rating of Buy (2.50/5) with a +75.0% upside to the consensus target of $29.95.
What are the earnings estimates for TNDM?
Analysts estimate TNDM will report EPS of $-0.75 for the period ending 2026-12-31, with revenue estimated at $1.08B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.